{"transactions":[{"id":691971,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T22:35:10.000Z","date":"2026-08-10","kind":"purchase","planned":false,"acquired":true,"shares":6000,"price":16,"value":96000.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001478916-26-000015","document":"form4-08102026_100806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000147891626000015/form4-08102026_100806.xml","form_type":"4"}},{"id":734020,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-17T20:05:25.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001478916-26-000012","document":"form4-06172026_040617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000012/form4-06172026_040617.xml","form_type":"4"}},{"id":734019,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T20:05:25.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":37652,"source":{"system":"sec-edgar","filing":"0001478916-26-000012","document":"form4-06172026_040617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000012/form4-06172026_040617.xml","form_type":"4"}},{"id":734018,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-17T20:05:19.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001478916-26-000011","document":"form4-06172026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000011/form4-06172026_040610.xml","form_type":"4"}},{"id":734017,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T20:05:19.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":37652,"source":{"system":"sec-edgar","filing":"0001478916-26-000011","document":"form4-06172026_040610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000011/form4-06172026_040610.xml","form_type":"4"}},{"id":739753,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:06:45.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":7000,"derivative":{"exercise_price":17.81,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001478916-26-000010","document":"form4a-06122026_080641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000010/form4a-06122026_080641.xml","form_type":"4/A","original_submission_date":"2026-05-14"}},{"id":739752,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-12T20:06:45.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":2500,"derivative":{"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001478916-26-000010","document":"form4a-06122026_080641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000010/form4a-06122026_080641.xml","form_type":"4/A","original_submission_date":"2026-05-14"}},{"id":741782,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:15:26.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders."}],"balance_after":30000,"derivative":{"exercise_price":10.55,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001478916-26-000009","document":"form4-06112026_040611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000147891626000009/form4-06112026_040611.xml","form_type":"4"}},{"id":778908,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T20:05:22.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"In addition to the options to purchase a total of 42,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 107,320 shares of common stock, which options vest according to their terms."}],"balance_after":42000,"derivative":{"exercise_price":17.81,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001478916-26-000007","document":"form4-05142026_040516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000007/form4-05142026_040516.xml","form_type":"4"}},{"id":778907,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-05-14T20:05:22.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001478916-26-000007","document":"form4-05142026_040516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000007/form4-05142026_040516.xml","form_type":"4"}},{"id":802759,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":5500,"derivative":{"exercise_price":32.17,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802758,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":5500,"derivative":{"exercise_price":43.91,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802757,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":10.87,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802756,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":14.83,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802755,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":15.53,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802754,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":21.19,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802753,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":10600,"derivative":{"exercise_price":17.02,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802752,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":10600,"derivative":{"exercise_price":23.23,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802751,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":9200,"derivative":{"exercise_price":22.13,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802750,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":9200,"derivative":{"exercise_price":30.44,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802749,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":11000,"derivative":{"exercise_price":21.76,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802748,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":11000,"derivative":{"exercise_price":29.7,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802747,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":11000,"derivative":{"exercise_price":12.14,"expiration_date":"2030-02-11","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802746,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":11000,"derivative":{"exercise_price":16.56,"expiration_date":"2030-02-11","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802745,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":6000,"derivative":{"exercise_price":50.47,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802744,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":6000,"derivative":{"exercise_price":68.88,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802743,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":6000,"derivative":{"exercise_price":76.79,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802742,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":6000,"derivative":{"exercise_price":104.81,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802741,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":15000,"derivative":{"exercise_price":18.03,"expiration_date":"2027-02-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802740,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:09.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":15000,"derivative":{"exercise_price":24.6,"expiration_date":"2027-02-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001478916-26-000006","document":"form4-04222026_100405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000006/form4-04222026_100405.xml","form_type":"4"}},{"id":802739,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":4000,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":802738,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6030,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":802737,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":5500,"derivative":{"exercise_price":11.75,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":802736,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":3.97,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":802735,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":5.67,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":802734,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":10600,"derivative":{"exercise_price":6.22,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":802733,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":9200,"derivative":{"exercise_price":8.14,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":802732,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":11000,"derivative":{"exercise_price":7.95,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":802731,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":11000,"derivative":{"exercise_price":4.43,"expiration_date":"2030-02-11","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":802730,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":6000,"derivative":{"exercise_price":18.43,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":802729,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":6000,"derivative":{"exercise_price":28.03,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":802728,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:20.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":15000,"derivative":{"exercise_price":6.58,"expiration_date":"2027-02-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001478916-26-000005","document":"form4-04222026_040415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000005/form4-04222026_040415.xml","form_type":"4"}},{"id":822794,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-02T01:28:11.000Z","date":"2026-03-30","kind":"sale","planned":false,"acquired":false,"shares":522,"price":57.3989,"value":29962.2258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.21 to $57.92 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":31622,"source":{"system":"sec-edgar","filing":"0001478916-26-000004","document":"form4-04022026_010407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000004/form4-04022026_010407.xml","form_type":"4"}},{"id":822793,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-02T01:28:11.000Z","date":"2026-03-30","kind":"sale","planned":false,"acquired":false,"shares":7527,"price":56.7002,"value":426782.4054,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.20 to $57.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":32144,"source":{"system":"sec-edgar","filing":"0001478916-26-000004","document":"form4-04022026_010407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000004/form4-04022026_010407.xml","form_type":"4"}},{"id":822792,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-02T01:28:11.000Z","date":"2026-03-30","kind":"sale","planned":false,"acquired":false,"shares":12596,"price":55.7087,"value":701706.7852,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.20 to $56.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":39671,"source":{"system":"sec-edgar","filing":"0001478916-26-000004","document":"form4-04022026_010407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000004/form4-04022026_010407.xml","form_type":"4"}},{"id":943180,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-01-08T21:04:03.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":4000,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001478916-26-000001","document":"form4-01082026_090159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000001/form4-01082026_090159.xml","form_type":"4"}},{"id":943179,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T21:04:03.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":5500,"derivative":{"exercise_price":43.91,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001478916-26-000001","document":"form4-01082026_090159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891626000001/form4-01082026_090159.xml","form_type":"4"}},{"id":959582,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T21:29:29.000Z","date":"2025-12-23","kind":"other","planned":false,"acquired":false,"shares":11068,"price":51,"value":564468.0,"ownership":{"direct":false,"nature":"By ESOP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold under the SpeakInc. Employee Ownership Plan (\"Plan\") of which the Reporting Person is a trustee of the Plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported shares are held by the Plan of which the Reporting Person is a trustee of the Plan.  The Reporting Person has less than 1% of a pecuniary interest in the Plan and disclaims beneficial ownership of these shares to the amount in excess of such Report Person's pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001478916-25-000004","document":"form4-12232025_091225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000147891625000004/form4-12232025_091225.xml","form_type":"4"}},{"id":1070332,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Class B ordinary shares","published_at":"2025-08-11T21:00:11.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-074364","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025074364/ownership.xml","form_type":"4"}},{"id":1070331,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock","published_at":"2025-08-11T21:00:11.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001213900-25-074364","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025074364/ownership.xml","form_type":"4"}},{"id":1107889,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-17T22:30:00.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":false,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001415889-25-017587","document":"form4-06172025_100656.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000141588925017587/form4-06172025_100656.xml","form_type":"4"}},{"id":1107888,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T22:30:00.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":52267,"source":{"system":"sec-edgar","filing":"0001415889-25-017587","document":"form4-06172025_100656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000141588925017587/form4-06172025_100656.xml","form_type":"4"}},{"id":1113579,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:30:16.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over 12 months following June 10, 2025 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001415889-25-016958","document":"form4-06122025_040611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000141588925016958/form4-06122025_040611.xml","form_type":"4"}},{"id":1189726,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-27T20:10:12.000Z","date":"2025-03-25","kind":"other","planned":false,"acquired":true,"shares":11068,"price":18.1822,"value":201240.5896,"ownership":{"direct":false,"nature":"By ESOP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased under the SpeakInc. Employee Ownership Plan (\"Plan\") of which the Reporting Person is a trustee of the Plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported shares are held by the Plan of which the Reporting Person is a trustee of the Plan.  The Reporting Person has less than 1% of a pecuniary interest in the Plan and disclaims beneficial ownership of these shares to the amount in excess of such Report Person's pecuniary interest."}],"balance_after":11068,"source":{"system":"sec-edgar","filing":"0001415889-25-009100","document":"form4-03272025_080308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000141588925009100/form4-03272025_080308.xml","form_type":"4"}},{"id":1302570,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-15T22:04:11.000Z","date":"2025-01-13","kind":"exercise","planned":false,"acquired":false,"shares":20645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.54,"expiration_date":"2025-11-15","underlying":"Common Stock","underlying_shares":20645},"source":{"system":"sec-edgar","filing":"0001415889-25-001501","document":"form4-01152025_100107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000141588925001501/form4-01152025_100107.xml","form_type":"4"}},{"id":1302569,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-15T22:04:11.000Z","date":"2025-01-13","kind":"exercise","planned":false,"acquired":false,"shares":21692,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.55,"expiration_date":"2025-06-09","underlying":"Common Stock","underlying_shares":21692},"source":{"system":"sec-edgar","filing":"0001415889-25-001501","document":"form4-01152025_100107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000141588925001501/form4-01152025_100107.xml","form_type":"4"}},{"id":1302568,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-15T22:04:11.000Z","date":"2025-01-13","kind":"exercise","planned":false,"acquired":true,"shares":20645,"price":8.54,"value":176308.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercises reported on this Form 4 for various stock options are expiring in 2025 and the Reporting Person wished to facilitate the exercises of such options before their expiration.  The Reporting Person does not intend to currently sell any of the said exercised shares in this Form 4."}],"balance_after":46237,"source":{"system":"sec-edgar","filing":"0001415889-25-001501","document":"form4-01152025_100107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000141588925001501/form4-01152025_100107.xml","form_type":"4"}},{"id":1302567,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-15T22:04:11.000Z","date":"2025-01-13","kind":"exercise","planned":false,"acquired":true,"shares":21692,"price":4.55,"value":98698.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercises reported on this Form 4 for various stock options are expiring in 2025 and the Reporting Person wished to facilitate the exercises of such options before their expiration.  The Reporting Person does not intend to currently sell any of the said exercised shares in this Form 4."}],"balance_after":25592,"source":{"system":"sec-edgar","filing":"0001415889-25-001501","document":"form4-01152025_100107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000141588925001501/form4-01152025_100107.xml","form_type":"4"}},{"id":1306668,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-08T14:16:11.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":2.81,"expiration_date":"2034-06-16","underlying":"Common Stock","underlying_shares":27350},"source":{"system":"sec-edgar","filing":"0001415889-25-001088","document":"form4-01082025_070107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001088/form4-01082025_070107.xml","form_type":"4"}},{"id":1306667,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-08T14:16:11.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":2.47,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":27350},"source":{"system":"sec-edgar","filing":"0001415889-25-001088","document":"form4-01082025_070107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001088/form4-01082025_070107.xml","form_type":"4"}},{"id":1306666,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-08T14:16:11.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":2.01,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0001415889-25-001088","document":"form4-01082025_070107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001088/form4-01082025_070107.xml","form_type":"4"}},{"id":1306665,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-08T14:16:11.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":8.63,"expiration_date":"2031-07-22","underlying":"Common Stock","underlying_shares":25833},"source":{"system":"sec-edgar","filing":"0001415889-25-001088","document":"form4-01082025_070107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001088/form4-01082025_070107.xml","form_type":"4"}},{"id":1306664,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-08T14:16:11.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":8.98,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-25-001088","document":"form4-01082025_070107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001088/form4-01082025_070107.xml","form_type":"4"}},{"id":1306663,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-08T14:16:11.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2030-07-08","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-25-001088","document":"form4-01082025_070107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001088/form4-01082025_070107.xml","form_type":"4"}},{"id":1306662,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-08T14:16:11.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16038,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":11.74,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":16038},"source":{"system":"sec-edgar","filing":"0001415889-25-001088","document":"form4-01082025_070107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001088/form4-01082025_070107.xml","form_type":"4"}},{"id":1306661,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-08T14:16:11.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":12,"expiration_date":"2028-07-16","underlying":"Common Stock","underlying_shares":32076},"source":{"system":"sec-edgar","filing":"0001415889-25-001088","document":"form4-01082025_070107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001088/form4-01082025_070107.xml","form_type":"4"}},{"id":1306660,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-08T14:16:11.000Z","date":"2025-01-08","kind":"other","planned":false,"acquired":false,"shares":58950,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent (\"Merger Sub\").  On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $9.00 per Share in cash (the \"Cash Amount\"), and (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").  Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent (\"Merger Sub\").  On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $9.00 per Share in cash (the \"Cash Amount\"), and (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").  Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-001088","document":"form4-01082025_070107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001088/form4-01082025_070107.xml","form_type":"4"}},{"id":1307932,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-01-07T22:28:24.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6030,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001415889-25-001036","document":"form4-01072025_100120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000141588925001036/form4-01072025_100120.xml","form_type":"4"}},{"id":1307931,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T22:28:24.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on Februray 7, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":16510,"derivative":{"exercise_price":14.83,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001415889-25-001036","document":"form4-01072025_100120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000141588925001036/form4-01072025_100120.xml","form_type":"4"}},{"id":1434794,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-13T20:15:08.000Z","date":"2024-08-12","kind":"purchase","planned":false,"acquired":true,"shares":4515,"price":2.2474,"value":10147.011,"ownership":{"direct":false,"nature":"By: The Schmid Family Trust dated August 15, 2017"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":25200,"source":{"system":"sec-edgar","filing":"0001867096-24-000176","document":"wk-form4_1723580007.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000186709624000176/wk-form4_1723580007.xml","form_type":"4"}},{"id":1435957,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T22:28:50.000Z","date":"2024-08-09","kind":"purchase","planned":false,"acquired":true,"shares":4285,"price":2.365,"value":10134.025,"ownership":{"direct":false,"nature":"By: The Schmid Family Trust dated August 15, 2017"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":20685,"source":{"system":"sec-edgar","filing":"0001867096-24-000173","document":"wk-form4_1723501724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000186709624000173/wk-form4_1723501724.xml","form_type":"4"}},{"id":1475193,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-06-19T00:17:01.000Z","date":"2024-06-15","kind":"exercise","planned":false,"acquired":false,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001415889-24-017510","document":"form4-06192024_120656.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000141588924017510/form4-06192024_120656.xml","form_type":"4"}},{"id":1475192,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-19T00:17:01.000Z","date":"2024-06-15","kind":"exercise","planned":false,"acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":3900,"source":{"system":"sec-edgar","filing":"0001415889-24-017510","document":"form4-06192024_120656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000141588924017510/form4-06192024_120656.xml","form_type":"4"}},{"id":1475308,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-18T16:16:43.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":27350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest and become fully exercisable on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":27350,"derivative":{"exercise_price":2.81,"expiration_date":"2034-06-16","underlying":"Common Stock","underlying_shares":27350},"source":{"system":"sec-edgar","filing":"0000950170-24-074875","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024074875/ownership.xml","form_type":"4"}},{"id":1475307,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-18T16:16:43.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":19650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":58950,"source":{"system":"sec-edgar","filing":"0000950170-24-074875","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024074875/ownership.xml","form_type":"4"}},{"id":1477398,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-17T21:00:21.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over 12 months following June 13, 2024 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":3.82,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001415889-24-017240","document":"form4-06172024_050618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000141588924017240/form4-06172024_050618.xml","form_type":"4"}},{"id":1489951,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:19:49.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 5, 2025 or the date of the Company's next annual meeting of stockholders."}],"balance_after":113159,"source":{"system":"sec-edgar","filing":"0001867096-24-000110","document":"wk-form4_1717618781.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000186709624000110/wk-form4_1717618781.xml","form_type":"4"}},{"id":1520610,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-10T20:04:26.000Z","date":"2024-05-10","kind":"purchase","planned":false,"acquired":true,"shares":5400,"price":1.91,"value":10314.0,"ownership":{"direct":false,"nature":"By: The Schmid Family Trust dated August 15, 2017"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":16400,"source":{"system":"sec-edgar","filing":"0001867096-24-000067","document":"wk-form4_1715371447.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000186709624000067/wk-form4_1715371447.xml","form_type":"4"}},{"id":1561952,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-25T23:10:26.000Z","date":"2024-03-25","kind":"purchase","planned":false,"acquired":true,"shares":17809,"price":3.74,"value":66605.66,"ownership":{"direct":false,"nature":"By Schmid Family Trust U/A dated 8-15-17"},"balance_after":26965,"source":{"system":"sec-edgar","filing":"0001415889-24-009063","document":"form4-03252024_110321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000141588924009063/form4-03252024_110321.xml","form_type":"4"}},{"id":1561951,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-25T23:10:26.000Z","date":"2024-03-22","kind":"purchase","planned":false,"acquired":true,"shares":9156,"price":3.6187,"value":33132.8172,"ownership":{"direct":false,"nature":"By Schmid Family Trust U/A dated 8-15-17"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $3.6187, and the range of prices were between $3.43 and $3.72.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is trustee of the trust."}],"balance_after":9156,"source":{"system":"sec-edgar","filing":"0001415889-24-009063","document":"form4-03252024_110321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000141588924009063/form4-03252024_110321.xml","form_type":"4"}},{"id":1576640,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-15T01:03:41.000Z","date":"2024-03-14","kind":"purchase","planned":false,"acquired":true,"shares":4500,"price":2.16,"value":9720.0,"ownership":{"direct":false,"nature":"By: The Schmid Family Trust dated August 15, 2017"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":11000,"source":{"system":"sec-edgar","filing":"0001867096-24-000034","document":"wk-form4_1710464612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000186709624000034/wk-form4_1710464612.xml","form_type":"4"}},{"id":1685432,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-01-05T21:58:15.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6030,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001209191-24-001050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000120919124001050/doc4.xml","form_type":"4"}},{"id":1685431,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T21:58:15.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on Februray 3, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":16510,"derivative":{"exercise_price":21.19,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001209191-24-001050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000120919124001050/doc4.xml","form_type":"4"}},{"id":1736626,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-17T23:35:56.000Z","date":"2023-11-16","kind":"purchase","planned":false,"acquired":true,"shares":6500,"price":1.51,"value":9815.0,"ownership":{"direct":false,"nature":"By: The Schmid Family Trust dated August 15, 2017"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001867096-23-000147","document":"wk-form4_1700264146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000186709623000147/wk-form4_1700264146.xml","form_type":"4"}},{"id":1852217,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-06-16T16:09:31.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":27350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest and become fully exercisable on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":27350,"derivative":{"exercise_price":2.47,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":27350},"source":{"system":"sec-edgar","filing":"0000950170-23-028607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017023028607/ownership.xml","form_type":"4"}},{"id":1852216,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T16:09:31.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":19650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":39300,"source":{"system":"sec-edgar","filing":"0000950170-23-028607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017023028607/ownership.xml","form_type":"4"}},{"id":1863840,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-07T20:55:22.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 7, 2024 or the date of the Company's next annual meeting of stockholders."}],"balance_after":63159,"source":{"system":"sec-edgar","filing":"0001867096-23-000093","document":"wk-form4_1686171315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000186709623000093/wk-form4_1686171315.xml","form_type":"4"}},{"id":1870162,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:31:46.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":5.63,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-033784","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919123033784/doc4.xml","form_type":"4"}},{"id":2057483,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-01-11T00:11:55.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":3900,"derivative":{"underlying":"Common Stock","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001209191-23-002885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000120919123002885/doc4.xml","form_type":"4"}},{"id":2057482,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-11T00:11:55.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":10600,"derivative":{"exercise_price":23.23,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001209191-23-002885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000120919123002885/doc4.xml","form_type":"4"}},{"id":2230094,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T21:10:11.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over 12 months following June 15, 2022 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":13.69,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-037517","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919122037517/doc4.xml","form_type":"4"}},{"id":2229956,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T20:56:00.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest and become fully exercisable on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":28500,"derivative":{"exercise_price":2.01,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0001209191-22-037667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000120919122037667/doc4.xml","form_type":"4"}},{"id":2229955,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-16T20:56:00.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":19650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":19650,"source":{"system":"sec-edgar","filing":"0001209191-22-037667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000120919122037667/doc4.xml","form_type":"4"}},{"id":2237700,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T21:13:58.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options will vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders."}],"balance_after":25000,"derivative":{"exercise_price":2.1,"exercise_date":"2022-06-08","expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001867096-22-000091","document":"wf-form4_165480922056229.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000186709622000091/wf-form4_165480922056229.xml","form_type":"4"}},{"id":2237699,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T21:13:58.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders."}],"balance_after":20659,"source":{"system":"sec-edgar","filing":"0001867096-22-000091","document":"wf-form4_165480922056229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000186709622000091/wf-form4_165480922056229.xml","form_type":"4"}},{"id":2397861,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-14T21:50:42.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":9200,"derivative":{"exercise_price":30.44,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001209191-22-009347","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000120919122009347/doc4.xml","form_type":"4"}},{"id":2548815,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:41:51.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":11228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders."}],"balance_after":11228,"derivative":{"exercise_price":3.9,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0000899243-21-039323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000089924321039323/doc4.xml","form_type":"4"}},{"id":2548814,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:41:51.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":11228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":11228,"derivative":{"exercise_price":4.68,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0000899243-21-039323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000089924321039323/doc4.xml","form_type":"4"}},{"id":2548813,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:41:51.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":20000,"derivative":{"exercise_price":10,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-21-039323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000089924321039323/doc4.xml","form_type":"4"}},{"id":2548812,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:41:51.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":25220,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":25220,"derivative":{"exercise_price":12.5,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":25220},"source":{"system":"sec-edgar","filing":"0000899243-21-039323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478916/000089924321039323/doc4.xml","form_type":"4"}}],"next_cursor":"2021-10-05T23:41:51.000000Z,2548812"}